Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements
December 15 2021 - 6:57AM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced that Apeiron Investment
Group, the family office of its Founder and Chairman, Christian
Angermayer, has decided to voluntarily extend its lock-up for all
of its pre-IPO common shares for another 24 months, subject to
limited exceptions. These shares represent approximately 17.4% of
atai’s outstanding common shares.
In addition, other of atai’s largest pre-IPO investors have
similarly signed voluntary agreements, extending their respective
lock-up restrictions for an additional 12 months, subject to
limited exceptions.
In the aggregate, these renewed lock-up agreements represent
over 30% of atai’s outstanding common shares and illustrate the
confidence of atai’s key shareholders in atai’s platform and its
potential to address the growing mental health crisis.
“I truly believe that atai Life Sciences is one of these rare
companies where the stars are aligned: the mission, the strategy,
the execution, and the macro-environment. I couldn’t be more
excited about atai’s future and its potential to play a vital role
in solving one of humanity’s biggest challenges – the,
unfortunately, continuously escalating mental health crisis,”
comments Christian Angermayer. “As a personal matter, it is
imperative to me to be on this journey for the long run, to leave
this world a better place, and to play a meaningful role in
bringing healing and relief to the millions and millions of people
currently suffering. I refuse to disappoint them.”
“For us, the IPO was just the beginning; another financing round
on a long term, entrepreneurial journey, all with the goal of
bringing new and better treatment options to people suffering from
mental health disorders. We are extremely grateful to have
Christian as a Founder, Chairman and investor. We are equally
grateful to our other key shareholders who have shown their support
and long-term commitment to atai through this unparalleled action,”
says Florian Brand, Co-Founder and CEO.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to
transform the treatment of mental health disorders. atai was
founded in 2018 as a response to the significant unmet need and
lack of innovation in the mental health treatment landscape. atai
is dedicated to acquiring, incubating and efficiently developing
innovative therapeutics to treat depression, anxiety, addiction,
and other mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. atai has
offices in New York, London, and Berlin. For more information,
please visit www.atai.life.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. The
words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “initiate,” “could,” “would,”
“project,” “plan,” “potentially,” “preliminary,” “likely,” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these words. Forward-looking statements include express or implied
statements relating to, among other things: continued investor
confidence in atai’s platform and its potential to serve the
growing mental health crisis; the success, cost and timing of
development of our product candidates; and our business strategy
and plans. The forward-looking statements in this press release are
neither promises nor guarantees, and you should not place undue
reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties, and other factors, many of
which are beyond our control and which could cause actual results,
levels of activity, performance or achievements to differ
materially from those expressed or implied by these forward-looking
statements.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. These
forward-looking statements are subject to a number of risks,
uncertainties, and assumptions, including without limitation the
important factors described in the section titled “Risk Factors” in
our final prospectus, dated June 17, 2021, filed with the
Securities and Exchange Commission (“SEC”) pursuant to Rule 424(b)
under the Securities Act, and in our other filings with the SEC,
that may cause our actual results, performance or achievements to
differ materially and adversely from those expressed or implied by
the forward-looking statements. Any forward-looking statements made
herein speak only as of the date of this press release, and you
should not rely on forward-looking statements as predictions of
future events. Although we believe that the expectations reflected
in the forward-looking statements are reasonable, we cannot
guarantee that the future results, performance, or achievements
reflected in the forward-looking statements will be achieved or
will occur. Except as required by applicable law, we undertake no
obligation to update any of these forward-looking statements for
any reason after the date of this press release or to conform these
statements to actual results or revised expectations.
Contact Information
For atai:
Media Contact:Camilla DormerVP, Communications, atai Life
SciencesEmail: camilla@atai.life
Investor Contact:Chad MesserVP, Investor Relations, atai Life
SciencesEmail: chad@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024